Detection of circulating tumor cells (CTCs) has been made to develop reliable assays for early diagnosis of various cancers. Overexpression of survivin in cancer cells is strongly associated with tumor progression. Although upregulation of survivin is observed in various tumors, its expression profile in the peripheral blood of prostate cancer (PCa) patients has not yet been investigated. In this study, we validated the application of survivin as the tumor marker to detect CTC and assessed its utility for diagnosis of PCa distant metastasis. Immunohistochemistry and quantitative real-time PCR (QRT-PCR) were performed to confirm the levels of surviving expression in PCa tissues. In addition, CTC values in 3 mL of peripheral blood from PCa patients, benign prostate hyperplasia (BPH) patients, and normal controls were also measured by the survivin-targeted PCR. Our results showed that surviving was overexpressed in PCa tissues. The median levels of blood surviving mRNA of PCa patients, BPH patients, and normal controls were 5.67 (range from 0 to 12.46), 2.24 (range from 0 to 6.55), and 1.85 (range from 0 to 3.82), respectively. The levels of survivin are positively associated with PCa distant metastasis. Our results concluded that quantitation of CTCs through survivin-PCR could be a promising marker for diagnosis of PCa metastasis.
Prostate cancer Circulating tumor cell Survivin mRNA Metastasis
This is a preview of subscription content, log in to check access.
This paper was supported by the National Key Basic Research Development Plan (973 Plan) (2011CB504302).
Zhu Y, Yang XQ, Han CT, Dai B, Zhang HL, Shi GH, et al. Pathological features of localized prostate cancer in China: a contemporary analysis of radical prostatectomy specimens. PLoS One. 2015;10(3), e0121076.CrossRefPubMedPubMedCentralGoogle Scholar
Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, et al. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol Oncol. 2014;32(6):761–8.CrossRefPubMedPubMedCentralGoogle Scholar
Bastian PJ et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007;13:5361–7.CrossRefPubMedGoogle Scholar
Danila DC et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053–8.CrossRefPubMedGoogle Scholar
Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13:688–95.CrossRefPubMedGoogle Scholar
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.CrossRefPubMedGoogle Scholar
Punnoose EA, Alwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18:2391–401.CrossRefPubMedGoogle Scholar
Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;4:46–54.CrossRefGoogle Scholar
Yie S-M, Luo B, Ye N-Y, et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis. 2006;23:279–89.CrossRefPubMedGoogle Scholar
Cao M, Yie S-M, Mu S-M, et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis. 2009;26:751–8.CrossRefPubMedGoogle Scholar
Yie S-M, Lou B, Ye S-R, et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer. 2009;63:284–90.CrossRefPubMedGoogle Scholar
Yie S-M, Lou B, Ye S-R, et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15:3073–82.CrossRefPubMedGoogle Scholar
Tang X-P, Li J, Yu L-C, et al. Clinical significance of surviving and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery. Lung Cancer. 2013;81:273–9.CrossRefPubMedGoogle Scholar
Livak KJ, Schimittgen TD. Analysis of reactive gene expression data using real-time quantitative PCR and 2−ΔΔCt method. Method. 2001;25:402–8.CrossRefGoogle Scholar
Lou J, Ben S, Yang G, Liang X, Wang X, Ni S, et al. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One. 2013;8(12), e80458.CrossRefPubMedPubMedCentralGoogle Scholar
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011;59(1):61–71.CrossRefPubMedGoogle Scholar